**Author Information** An event is serious (based on the ICH definition) when the patient outcome is:\* death\* life-threatening\* hospitalisation\* disability\* congenital anomaly\* other medically important event

A 72-year-old woman developed COVID-19 pneumonia, *Pneumocystis jirovecii and Aspergillus fumigatus infection*during treatment with leflunomide, methylprednisolone, prednisone and tocilizumab for rheumatoid arthritis \[*not all dosages stated*\].

The woman had a history of rheumatoid arthritis (RA) for nearly 30 years. She was on oral leflunomide 20mg daily for 10 years and was receiving oral hydroxychloroquine 0.4g per day from the last 1 year. On 5 January 2020, she had fever \[*aetiology not stated*\] along with cough, mild shortness of breath, and white but little expectoration. Chest CT scan revealed pneumonia in the right upper lobe (RUL) of her lungs. On 27 January 2020, a chest CT scan indicated a progression of the lesions in her RUL. On 28 January 2020, she tested positive for severe acute respiratory syndrome coronavirus-2 (SARS-Cov-2) RNA in her swab samples, and a diagnosis of coronavirus disease-2019 (COVID-19) was made. She started receiving off-label treatment with antiviral agents such as oseltamivir phosphate, oral lopinavir/ritonavir 1000 mg/day, and oral methylprednisolone 40mg, daily for 5 days. Following this, she had a significant relief of breath shortness and cough. On 03 February 2020, her Chest CT revealed significant absorption of lesions in her lungs. The dosage of glucocorticoids were tapered from 31 January 2020. Treatment with antiviral agents was withdrawn on 04 February 2020. On 11 February 2020, within 11 days of tapering methylprednisolone dose to 4mg per day, her body temperature rebounded to 38.4°C and ground-glass opacities (GGOs) and patchy shadows appeared in both of her lungs. The dosage of methylprednisolone was elevated to 16 mg/day and antiviral treatment with lopinavir/ritonavir was restarted. After 6 days, lesions in her lungs were absorbed totally and her body temperature returned to normal. On 18 February 2020, a taper of methylprednisolone was initiated and treatment with lopinavir/ritonavir was stopped. However, her fever emerged again after usage of methylprednisolone was stopped on 23 February 2020. She then received another similar round of therapy. On 02 March 2020, she presented with mild fever 37.7°C, along with shortness of breath and chest tightness. On 03 March 2020, she was admitted to hospital because of the recurrence and progression of the disease. On admission, her lab results indicated a decreased lymphocyte count in peripheral blood and elevated levels of C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR). Her serum IL-6 level was within normal range. An anti-SARSCoV-2 antibody detection revealed strong positivity of IgG subtype; but, it was negative for IgMsubtype. She started receiving treatment with oral prednisone 10mg per day. On 07 March 2020, her ESR and serum IL-6 level were found to be elevated. Chest CT scan revealed increased lesions in both of her lungs. Severe COVID-19 was considered; an IV drip administration of tocilizumab 400mg per day was initiated to target both RA and COVID-19. Also, the dosage of oral prednisone was increased (from 50mg per day to up to 150mg per day during this treatment period). On 10 March 2020, her condition deteriorated sharply despite the escalation of treatment. On 14 March 2020, her chest CT scan showed worsed condition on both her upper lungs and serum IL-6 level elevated to 260.1 pg/mL. Tocilizumab 400mg per day was then administered for the second time through IV drip. On 17 March 2020, she had severe dyspnoea, IL-6 elevated to 2055 pg/mL, and aggravation of lesions was observed on her upper lungs. Infection of other pathogens because of her over suppressed immune systems resulted from the administration of tocilizumab and/or glucocorticoids was considered as the aetiology by a multidisciplinary team. It was decided to detect the presence of potential pathogenic pathogens. Treatment with hydroxychloroquine was maintained.

Treatment with leflunomide was withdrawn. She then received treatment with ganciclovir sodium, cefoperazone/sulbactam, and caspofungin \[caspofungin acetate \] at the same time. Meanwhile, her serum ferritin level was found to be 2442 µg/L and her platelet count decreased continuously along with hypofibrinogenemia. On 21 March 2020, elevated serum IL-6, IL-2R, IL-8, and TNF-alpha levels were detected. All these indicated the tendency of secondary hemophagocytic lymphohistiocytosis (sHLH) characterised by a cytokine storm, multi-organ damage, and hemophagocytosis. Following this, methylprednisolone dose was also escalated. Thereafter, absorption of lesions was observed on chest CT scan.

On 22 March 2020, the high throughput sequencing analysis detected the presence of *Aspergillus fumigatus*and *Pneumocystis jirovecii.*On 24 March 2020, a chest CT scan revealed improvement, and levels of serum cytokines dropped significantly. She also received the application of blood products in combination with antimicrobial treatment. On 08 April 2020, her chest CT scan indicated significant absorption of lesions on her lungs. At this time, she could finish her daily activity without much effort. She tested negative for SARS-CoV-2, IgM antibody, and cytomegalovirus. She developed IgG antibodies. On 14 Apr 2020, she was discharged from the hospital.
